MindMed

As of today, psychedelics biotech Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will trade its common shares based on a 1-for-15 reverse share split, the company announced on Friday. The company executed the split on its outstanding Nasdaq and Neo Exchange shares at market open on...

The clinical-stage biopharma company Mind Medicine -also known as MindMed (NASDAQ: MNMD), which recently made headlines regarding its stock, announced it will begin dosing patients within its Phase 2b trial on LSD compound, MM-120, for the treatment of Generalized Anxiety Disorder (GAD)....

MindMed Inc. (NASDAQ: MNMD) reported favorable results for one of its proprietary compounds. The Phase 1 trial of MM-110 included 108 healthy volunteers and was designed to study the pharmacokinetics and neurocognitive effects of the substance, ensuring its safety and tolerability. MM-110 is...

MindMed (NASDAQ: MNMD) researchers shared topline clinical results for a Phase 2 LSD clinical study at the recent Psych Symposium, which was co-sponsored by University Hospital Basel (UHB). Prof. Matthias Liechti and Dr. Friederike Holze, MindMed collaborators at UHB, commented that...

Benzinga, a large content provider to brokerages and news outlets, hosts live conferences to recognize disruptive innovation in finance and technology, trading, and emerging assets. Two of those events – Benzinga’s Psychedelics and Cannabis Capital conferences – happened last week...

With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ: MNMD) is someone who certainly knows the ins and outs of the business. Barrow joined MindMed in January 2021 as Chief Development Officer (CDO) but was later appointed as CEO and...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Cash balance as of December 31, 2021, was $133.5 million compared to $80.1 million as of December 31, 2020. Net cash in operating activities was...

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second...

This article was originally published on Microdose and appears here with permission. MindMed ended its 2021 news cycle on a somewhat mehhh note. In late December we reported that the FDA has put a hold on MindMed’s submission for its Phase 2b trial of LSD for the treatment...

MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, announced on Dec. 21 that the  Food and Drug Administration (FDA) has placed a clinical hold on its...

This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning more about the changes that have taken place since, Benzinga spoke with Robert Barrow, the firm’s chief development...

Courtesy of: MindMed The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Despite the fact that around 450 million people globally suffer from mental illnesses, access to mental healthcare is...

A lot has changed since Benzinga last spoke with Kevin O’Leary, businessman, author, "Shark Tank's" Mr. Wonderful. Most notably, his deal flow is more so concentrated around emerging markets such as DeFi — a finance model that replicates market-making, borrowing, lending...